Minimalist Approach to T-AVR

Slides:



Advertisements
Similar presentations
STS 2015 John V. Conte, MD Professor of Surgery Johns Hopkins University School of Medicine On Behalf of the CoreValve US Investigators Transcatheter Aortic.
Advertisements

Trileaflet Aortic Valve. Management strategy for patients with chronic severe aortic regurgitation. Preoperative coronary angiography should be performed.
Long-Term Outcomes Using a Self- Expanding Bioprosthesis in Patients With Severe Aortic Stenosis Deemed Extreme Risk for Surgery: Two-Year Results From.
University Heart Center Hamburg
Dr Martyn Thomas Director of Cardiac Services Guys and St Thomas NHS Foundation Trust A Member of Kings Health Partners London.
One stage coronary and peripheral intervention Pawel Buszman, MD, American Heart of Poland, Ustron Silesian Medical School, Katowice.
Impact of Concomitant Tricuspid Annuloplasty on Tricuspid Regurgitation Right Ventricular Function and Pulmonary Artery Hypertension After Degenerative.
1 Investigational Device only in the U.S. Not available for sale in the U.S. ACCESS EU – ESC 2012 European Society of Cardiology Congress 2012 Munich,
A shifting paradigm of care: Advances in transcatheter heart valve procedures Sandra Lauck MSN, RN, CCN(C) Clinical Nurse Specialist, Arrhythmia Management.
Cardiac Intervention in the Elderly. Cardiac Interventions Coronary Artery Bypass Grafting (CABG) Percutaneous Transluminal Coronary Angioplasty (PTCA)
Glauber Mattia 1. Presenter disclosure information Dr Glauber disclose a financial relationship for educational program with Sorin Group. Dr Glauber is.
Trancatheter Aortic Valve Implantation (TAVI)
The Impact of Prior Stroke on the Outcome of Patients with Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement Romain Didier, MD;
Tri-leaflet Aortic Valve. Aortic Stenosis Nishimura, RA et al AHA/ACC Valvular Heart Disease Guideline.
GENDER DISPARITIES AMONG PATIENTS UNDERGOING TRANSCATHETER AORTIC VALVE REPLACEMENT Michael A. Gaglia, Jr.; Michael J. Lipinski; Rebecca Torguson; Jiaxiang.
MYOCARDIAL INFARCTION. CASE 1 Mr. A: 38 years old He smokes 1 pack of cigarettes per day He has no other past medical history 8 hours ago, he gets sharp.
Critical Appraisal Topic Acquil Mohammad U. Alip, MD Resident Dept. of Anesthesiology UP-PGH Manila, Philippines.
Ted Feldman MD, FACC, FESC, FSCAI Disclosure Information The following relationships exist: Grant support: Abbott, BSC, Edwards, St Jude, WL Gore Consultant:
Patient Selection & Risk Stratification Soltani GH, MD.
1 Heart surgery in Norway 2008 Norwegian Association of Cardiothoracic Surgeons Jan L.Svennevig, MD,PhD
Longest Follow-up After Implantation of a Self-Expanding Repositionable Transcatheter Aortic Valve: Final Follow-up of the Evolut R CE Study Stephen Brecker,
Carotid Access for TAVR: An underappreciated approach?
The Impact of Preoperative Renal Dysfunction on the Outcomes of Patients Undergoing Transcatheter Aortic Valve Replacement Andres M. Pineda MD, J. Kevin.
VSD post TAVR: Mechanisms, Presentation and Management
Atrial fibrillation J Heinsimer MD.
Disclosure Statement of Financial Interest
Patients at intermediate surgical risk undergoing isolated interventional or surgical aortic valve replacement for severe symptomatic aortic valve stenosis.
The German Off-Pump Coronary Artery Bypass Grafting in
Role of Device Therapy in FMR: Challenges and Opportunities
Pros and Cons of Radial Access
Initial center experience with the St
Raj R. Makkar, MD On behalf of The PARTNER Trial Investigators
The Role of the Heart Team in the Cath Lab in 2017
Direct Flow Medical Experience with a Conformable, Repositionable, Retrievable, Percutaneous Aortic Valve Reginald Low MD University of California,Davis.
30-Day Outcomes From John Webb, MD
Obstructive Hypertrophic Cardiomyopathy
Mayra Guerrero, MD, FACC, FSCAI
TAVR – The Trans-carotid Approach
Thirty-day Readmissions Following CABG Surgery in New York JACC: Cardiovascular Interventions 2011;4(5): Hannan EL, Zhong Y, Lahey SJ, Culliford.
MedStar Washington Hospital Center Cardiac Catheterization Conference
First Report of One-Year Outcomes of the REPRISE I Feasibility Study of the Repositionable Lotus Aortic Valve Replacement System Ian T. Meredith.
30-Day Safety and Echocardiographic Outcomes Following Transcatheter Aortic Valve Replacement with the Self-Expanding Repositionable Evolut PRO System.
University of Cincinnati Medical Center
The Spanish Data Bank PEGASO M. Martínez-Sellés
30 Day Outcomes from the SOURCE XT TAVI Post Approval Study
Is There a Need to Address AF in patients Undergoing Valve Surgery?
First Report of Three-Year Outcomes With the Repositionable and Fully Retrievable Lotus™ Aortic Valve Replacement System: Results From the REPRISE I.
University of Pennsylvania
Washington Hospital Center
Early Recovery of Left Ventricular Systolic Function After CoreValve Transcatheter Aortic Valve Replacement Harold L. Dauerman, MD; Michael J. Reardon,
Direct Flow Medical Experience with a Conformable, Repositionable Retrievable Percutaneous Aortic Valve Reginald Low MD University of California, Davis.
TAVI „Catch me if you can!“
The Impact of Live Case Transmission on Patient Outcomes during Transcatheter Aortic Valve Replacement: Results from the VERITAS Study Dr. Ron Waksman.
Early Feasibility Studies Investigator Perspective
EVEREST II 5-Year Report and Beyond
Vinod H. Thourani, MD on behalf of The PARTNER Trial Investigators
Progress with the Sadra Medical Lotus™ Valve System
Jan L.Svennevig, MD,PhD Heart surgery in Norway 2007 Norwegian Association of Cardiothoracic Surgeons Jan L.Svennevig, MD,PhD.
Managing and Correcting a "Frozen" Leaflet after TAVR
University Heart Center Hamburg
Balloon-Expandable Transcatheter Valve System : OUS Data
Conscious Sedation March, 2012.
Cardiac Cath NUR 422.
Late Follow-Up from the PARTNER Aortic Valve-in-Valve Registry
Cardiovacular Research Technologies
Coronary Revascularization and TAVR
Shikhar Agarwal, MD, MPH, Aatish Garg, MD, Akhil Parashar, MD, Lars G
New-Onset Postoperative Atrial Fibrillation and Long-Term Survival After Aortic Valve Replacement Surgery  Giovanni Filardo, PhD, MPH, Cody Hamilton,
Five-Year Outcomes after Randomization to Transcatheter or Surgical Aortic Valve Replacement: Final Results of The PARTNER 1 Trial Michael J. Mack, MD.
Role of Anesthesiologists/CRNA in an Office Interventional Suite
Presentation transcript:

Minimalist Approach to T-AVR Pichard, L. Satler, R Waksman, I Ben-Dor, G Maluenda, P. Corso, S Boyce, K Kent, W Suddath, N Bernardo, S Goldstein, Z Wang, G Weissman, G Weigold, J Lindsay, J Panza

Gus Pichard, MD Edwards Lifesciences. Proctor St Jude Medical. Speaker Bureau

Percutaneous Aortic Valve without Intubation

Mitral Valvuloplasty with TEE

TEE without Intubation in the Cath Lab. Abstract Presented Sept 2000. 700 procedures Average duration of TEE 60 minutes Procedure well-tolerated No complications related to TEE 5

At the Washington Hospital Center Cath Labs we use TEE for: All mitral valvuloplasties (>1000 patients). All alcohol septal ablations (± 25/year). All ASD/PFO closures until 2008, when TEE was replaced with ICE. Other structural HD (LAA closure, LV parachute, MV clip, VSD closure, etc). Percutaneous aortic valves.

Protocol for TEE in Cath Lab. Standard conscious sedation is initiated (Fentonyl and Versed) by the cath lab nurse. Have never used anesthesiology. TEE probe is introduced as the femoral sheaths are placed. Intervention proceeds under continuous TEE guidance. Patient is awake at end of procedure and is informed about the results of the procedure in the company of his/her family.

Is TEE needed for T-AVR? We always use it (protocol reasons). Probably not needed for valve deployment. Important for analysis of AR post implant. Essential for analysis of complications: - marked hypotension - valve malfunction or malposition.

Conscious Sedation Protocol for TF T-AVR Anesthesiologist assesses patient the day before. Anesthesiologist in the Lab Anesthesia equipment in the Lab Anesthesiologist has the usual set up for cardiac anesthesia: Swan through IJV, radial artery pressure, etc. Anesthesia monitors BP, PAP, 02 and C02, CO. Generous Lidocaine at the access site in the groin.

Drugs used for Conscious Sedation A. Start with VERY light sedation: 1mg versed , 50 mcg Fentonyl while placing A-line, and right IJ Swan. B. Maitenance drugs. 2 protocol options: 1. "Ketaphol" 10mg Ketamine with 200mg (20cc) Propofol. Dose: Propofol 10mcg/kg/min and up to 75 mcg/kg/min. Ketamine adds some analgesia with less respiratory depression than Propofol alone. 2. Dexmetetomidine (Precedex) (sedative used in the ICU with little hemodynamic consequence and minimal respiratory depression). Can be started without any other drugs. Dose: 0.3-0.7mcg/kg/hr with or without a bolus.

Variable Conscious sedation N=70 General anesthesia N=22 P value Age (years) 84.1±5.1 83.7 ± 7.9 0.8 Female 41(58.5%) 14 (63.6 %) 0.3 Society of Thoracic Surgeons score (%) 11.3±3.4 10.9±3.7 0.6 Logistic EuroSCORE 40.1±19.4 28.1±16.1 0.01 High risk surgical 42(60%) 11(50%) 0.7 Non-surgical candidate 28(40%) NYHA class IV 34(48.6%) 12(54.5%) Diabetes 21(30.0%) 7(31.8%) Hypertension 63(90.0%) 21(95.5%) 0.4 Coronary artery disease 39(55.7%) 10(45.5%) Prior myocardial infarction 13(18.6%) 2(9.1%) Prior CABG 23(32.8%) 6(27.2%) COPD 10(14.3%) Renal failure (CrCl <60 ml/min) 26(37.1%) 11(50.0%) Prior CVA/TIA 0.04 Atrial fibrillation 30(42.8%)

Conscious Sedation vs. General Anesthesia Procedure Duration (minutes) ICU Stay (hours) Hospital Stay (days)

Conversion to Intubation 8(11.4%) converted to general anesthesia. 3(4.2%) due to respiratory failure. 2(2.8%) due to hemodynamic compromise. 3(4.2%) retroperitoneal approach was required.

Minimalist Approach: Alain Cribier A. Cribier WHC Intubation No TEE Yes Swan Ganz Radial artery pressure Gradients pre-post Heart-Lung Equipm. in room Vascular Instruments Table Percutaneous Access

Conclusions PHV with TEE guidance is perfectly feasible without intubation. All the side effects of general anesthetics are avoided. No safety concerns. No increased discomfort to the patient. We highly recommend it!

The end

PHV with Concious Sedation and NO intubation 74 year old male PMH: Severe COPD FEV1 - 0.76, 30% predicted PCO2 - 68 mmHg, pO2 50. On Home Oxygen Recurrent GI bleed of unknown origin Diabetic. 262 pounds. Seen by 3 pulmonary specialists and by Cardiac Surgery Not operative candidate Cohort B

PHV on 2/21/08 Surgical access: very deep to reach, took >25 min Tunneled the sheath Dilators went up easy. Same with large sheath. TEE: annulus 23-24 mm 26 mm valve delivered without problems. Excellent position. 1+ AR No intubation, tolerated case very very well. Was talking at the end of the case. Duration: 8 am to 10 am.